Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-MIPS
- Development stage
- Preclinical
- Lead developer
- Monash University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
18F-MIPS (also known as [18F]MIPS15692) is a novel fluorine-18 labeled small molecule positron emission tomography (PET) radiotracer designed to target MER tyrosine kinase (MERTK). MERTK is a tyrosine kinase expressed on reparative (M2-polarized) microglia, which play a vital role in neuroregeneration and phagocytosis following central nervous system damage. Developed by researchers at Monash University, the Florey Institute of Neuroscience and Mental Health, and Austin Hospital, 18F-MIPS is being investigated as an imaging biomarker to detect and track neuroregenerative processes in neuroinflammatory and neurodegenerative diseases, such as multiple sclerosis (MS) and epilepsy. Preclinical studies in animal models of demyelination (cuprizone mouse model) and epilepsy (post-kainic acid rat model) have demonstrated its selectivity and potential to visualize reparative microglia in vivo.
- Other names
- [18F]MIPS-15692[18F]MIPS15692
02
Targets
MERTK (MER proto-oncogene, tyrosine kinase)
Beyond the preview
Go deeper on 18F-MIPS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-MIPS.